This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Concert Pharmaceuticals Future Growth
Future criteria checks 2/6
Key information
38.9%
Earnings growth rate
43.3%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 54.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Mar 2023 |
Recent future growth updates
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 96 | -69 | N/A | -86 | 2 |
| 12/31/2024 | 29 | -129 | N/A | -140 | 2 |
| 12/31/2023 | 18 | -137 | N/A | -78 | 3 |
| 12/31/2022 | 0 | -122 | N/A | N/A | 3 |
| 9/30/2022 | 32 | -127 | -110 | -110 | N/A |
| 6/30/2022 | 33 | -125 | -103 | -102 | N/A |
| 3/31/2022 | 33 | -95 | -67 | -67 | N/A |
| 12/31/2021 | 33 | -80 | -55 | -55 | N/A |
| 9/30/2021 | 1 | -66 | -45 | -45 | N/A |
| 6/30/2021 | 2 | -59 | -47 | -47 | N/A |
| 3/31/2021 | 8 | -77 | -72 | -72 | N/A |
| 12/31/2020 | 8 | -75 | -69 | -69 | N/A |
| 9/30/2020 | 8 | -73 | -68 | -68 | N/A |
| 6/30/2020 | 6 | -71 | -64 | -63 | N/A |
| 3/31/2020 | 0 | -77 | -66 | -65 | N/A |
| 12/31/2019 | 1 | -78 | -49 | -49 | N/A |
| 9/30/2019 | 1 | -79 | -50 | -49 | N/A |
| 6/30/2019 | 1 | -79 | -47 | -45 | N/A |
| 3/31/2019 | 1 | -73 | -40 | -37 | N/A |
| 12/31/2018 | 11 | -56 | -51 | -48 | N/A |
| 9/30/2018 | 11 | -41 | -41 | -39 | N/A |
| 6/30/2018 | 11 | 104 | 104 | 106 | N/A |
| 3/31/2018 | 11 | 104 | 104 | 105 | N/A |
| 12/31/2017 | 0 | 95 | 103 | 104 | N/A |
| 9/30/2017 | 0 | 89 | 98 | 99 | N/A |
| 6/30/2017 | 0 | -50 | -46 | -45 | N/A |
| 3/31/2017 | 0 | -50 | -45 | -44 | N/A |
| 12/31/2016 | 0 | -51 | -46 | -45 | N/A |
| 9/30/2016 | 10 | -38 | -33 | -33 | N/A |
| 6/30/2016 | 12 | -35 | N/A | -30 | N/A |
| 3/31/2016 | 15 | 19 | N/A | 20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNCE's revenue (54.9% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: CNCE's revenue (54.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time